Trimetazidine As a Modifier of Chemotherapy-Induced Cardiovascular Redox-Homeostasis Disturbances Publisher



Avagimyan A¹ ; Heshmatghahdarijani K² ; Kakturskiy L³
Source: Kardiologija v Belarusi Published:2022

Abstract

Introduction. Our research was determined to investigate the Adriamycin + Cyclophosphamide (AC)-mode of chemotherapy-related disturbances of cardiovascular (CV) homeostasis, and possibility of trimetazidine (TMZ)-induced cardioprotection. Purpose. Assess oxidative state of myocardium during AC-mode of chemotherapy administration, and justification of trimetazidine prescription among under-treatment and post-treatment cancer patient. Materials and methods. For this study, 80 inbred Wistar rats were randomly divided into four equal experimental groups. A model of lipid peroxidation (LPO)-induced myocardial injury, was attained via doxorubicin and cyclophosphamide co-administration. Trimetazidine was used as a probable limiter of heart and vessels morpho-functional homeostasis aggravations. Results. The markers of redox-balance, were determined and assessed. The data obtained showed that this TMZ modified the intensification of lipid peroxidation. Conclusions: 1. AC-mode of chemotherapy has LPO-stimulating and antioxidant-limiting impact. 2. TMZ provide statistically significant and valuable normalization of redox-homeostasis. © 2022, Professionalnye Izdaniya. All rights reserved.